Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.46 USD

37.46
3,663,909

+0.65 (1.77%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $37.44 -0.02 (-0.05%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

by Zacks Equity Research

AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

    Zacks Equity Research

    Exelixis's Cabometyx Positive for First-Line Kidney Cancer

    by Zacks Equity Research

    Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

      Zacks Equity Research

      Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

      by Zacks Equity Research

      Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

        Zacks Equity Research

        Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

        by Zacks Equity Research

        Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

          Zacks Equity Research

          Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?

          by Zacks Equity Research

          Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Zacks Equity Research

            Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

            by Zacks Equity Research

            Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy

              Zacks Equity Research

              Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

              by Zacks Equity Research

              Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

                Zacks Equity Research

                Play Potential Earnings Beat with These 5 Top-Ranked Stocks

                by Zacks Equity Research

                Bet on these top-ranked stocks that have the potential to beat the earnings estimate.

                  Zacks Equity Research

                  Is Intercept (ICPT) Poised for a Beat This Earnings Season?

                  by Zacks Equity Research

                  Is Intercept (ICPT) Poised for a Beat this Earnings Season?

                    Zacks Equity Research

                    Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?

                    by Zacks Equity Research

                    Apple, Inc. (AAPL) is set to report its second-quarter fiscal 2017 results on May 2.

                      Zacks Equity Research

                      What to Expect from Quotient Technology (QUOT) Q1 Earnings?

                      by Zacks Equity Research

                      Quotient Technology Inc. (QUOT) is set to report first-quarter 2017 results on May 2.

                        Zacks Equity Research

                        Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?

                        by Zacks Equity Research

                        Insperity, Inc. (NSP) is set to report first-quarter 2017 results on May 1.

                          Zacks Equity Research

                          Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                          by Zacks Equity Research

                          Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                            Zacks Equity Research

                            Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis

                            by Zacks Equity Research

                            Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis

                              Arpita Dutt headshot

                              M&As, Pipeline Catalysts to Drive Pharma Sector

                              by Arpita Dutt

                              The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.

                                Zacks Equity Research

                                Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

                                by Zacks Equity Research

                                Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                                  Zacks Equity Research

                                  Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC

                                  by Zacks Equity Research

                                  Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC

                                    Zacks Equity Research

                                    Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?

                                    by Zacks Equity Research

                                    The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.

                                      Tirthankar Chakraborty headshot

                                      4 Stocks to Buy with Superb Earnings Acceleration

                                      by Tirthankar Chakraborty

                                      Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price.

                                        Zacks Equity Research

                                        Keryx (KERX) Q4 Earnings: What's in Store for the Stock?

                                        by Zacks Equity Research

                                        Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.

                                          Zacks Equity Research

                                          Radius Health (RDUS) Posts Wider Loss in Q4

                                          by Zacks Equity Research

                                          Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.

                                            Zacks Equity Research

                                            What's in the Cards for Box, Inc. (BOX) in Q4 Earnings?

                                            by Zacks Equity Research

                                            Box, Inc. (BOX) is set to report fourth-quarter fiscal 2017 results on Mar 1. Last quarter, the company posted a positive earnings surprise of 14.29%.

                                              Zacks Equity Research

                                              Why Earnings Season Could Be Great for Exelixis (EXEL)

                                              by Zacks Equity Research

                                              Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                                Zacks Equity Research

                                                DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?

                                                by Zacks Equity Research

                                                DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.

                                                  Zacks Equity Research

                                                  Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?

                                                  by Zacks Equity Research

                                                  Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.